BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T144702
CREATED:20240805T120321Z
LAST-MODIFIED:20240805T120321Z
UID:39498-1731369600-1731628799@www.pharmajournalist.com
SUMMARY:Hit ID Summit
DESCRIPTION:Discover the future of drug discovery at the inaugural Hit ID Summit! As chemical libraries and hit screening methods—including DNA-encoded libraries\, high-throughput screening\, fragment-based screening\, and AI—continue to evolve\, now is the time for medicinal chemists\, computational chemists\, and drug discovery leaders and innovators to unite at a dedicated forum. This unique event presents the opportunity to share innovative ideas and actionable insights that will revolutionize hit finding strategies and propel the entire drug development process forward. From delving into the latest hit-finding technologies and methodologies\, bridging the gap from target identification to molecule discovery and transforming hits into promising leads. \nJoin us for an unmissable experience where the biggest names in pharma and biotech come together including AstraZeneca\, Bristol Myers Squibb\, GlaxoSmithKline\, Insitro\, Sanofi & more. This is your chance to stay ahead of the curve and drive innovation in your hit identification and drug discovery strategies. \nDon’t miss out on this unique opportunity to network with over 50 hit strategy specialists and drug discovery experts. With insights from industry giants like AbbVie\, AstraZeneca\, Novartis\, Pfizer\, Sanofi\, and UCB\, gain invaluable knowledge and forge meaningful connections that will take your work to the next level. \nTo know more visit: https://ter.li/fifhhn%20
URL:http://www.pharmajournalist.com/event/hit-id-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T144702
CREATED:20240815T164037Z
LAST-MODIFIED:20240815T164037Z
UID:39582-1731369600-1731628799@www.pharmajournalist.com
SUMMARY:8th Dermatology Drug Development Summit
DESCRIPTION:The advanced therapy immuno-inflammatory dermatology market is undergoing unprecedented expansion\, as Johnson & Johnson make a $3.35B play for bispecific candidates\, Alumis secured $259M series C and Galderma\, Incyte\, and Eli Lilly unveil late-breaking data. \nWith a fast-evolving drug development landscape\, remaining at the forefront of promising targets is now more crucial than ever. That’s why we’re delighted to announce the return of the 8th Dermatology Drug Development Summit (November 12-14 | Boston\, MA)\, the definitive industry-led forum uniting 130+ large pharma\, biotech\, and clinician KOLs to discover and develop best-in-class drugs for immuno-inflammatory skin disease. \nExplore the end-to-end conference program here: https://ter.li/5j7wx4 \nFeaturing 30+ expert speakers from the likes of Alys Pharmaceuticals\, LEO Pharma\, Incyte and AbbVie\, program highlights include: \n\n2 NEW tracks on Discovery & Translation to the Clinic and Clinical & Commercial Strategy\, providing more depth of content supporting disease pathogenesis understandings and novel target validation\, through demonstrating durable clinical efficacy whilst navigating nuanced market access challenges\n4 hands-on workshops pairing data-driven insights with collaborative problem-solving discussions to drive therapeutic progress in Hidradenitis Suppurativa\, JAK Inhibitors and Assets Targeting Multiple Indications\, plus laying foundations for Recruitment and Retention finesse.\n\nIncreased drug development landscape visibility\, including clinical case studies from early to late-stage programs\, all with dedicated Q&A time\, for Monoclonal Antibodies\, Oral and Topical Small Molecules\, Oral Peptides\, siRNA Lipid Conjugates\, Bispecific Antibodies and more! \nHere’s a snapshot of who you will meet: \nTakeda | MoonLake Immunotherapeutics | Seagen | Astria Therapeutics | Aditum Bio | Shaperon | Lynk Pharma | CAGE Bio | Sanofi | Edesa Biotech | Arcutis Biotherapeutics | AbbVie | GSK | Carocell Bio | Enveda Biosciences | Zura Bio | Incyte | UNION Therapeutics | Merck | Hudson Therapeutics | J&J | LEO Pharma | Recludix Pharma | Lynk Pharmaceuticals \nStay ahead of the scientific and commercial challenges in inflammatory disease drug development to set yourself up for success in 2025! \nQuick links: Website | Event Guide | Contact Us
URL:http://www.pharmajournalist.com/event/8th-dermatology-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241113
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T144702
CREATED:20240815T164748Z
LAST-MODIFIED:20240819T230624Z
UID:39587-1731456000-1731628799@www.pharmajournalist.com
SUMMARY:World Companion Diagnostics & Liquid Biopsy Summit APAC
DESCRIPTION:In the last 12 months\, precision healthcare in the Asia-Pacific region has seen a surge in technology advancements\, including NGS and laboratory developed tests\, approvals such as a companion diagnostic test for lung cancer\, and evolving regulations throughout the region. \nThe World Companion Diagnostics & Liquid Biopsy Summit APAC has been put together to provide a dedicated forum for key stakeholders from biopharma\, diagnostic providers and leading academics to overcome critical challenges in liquid biopsy and companion diagnostic (CDx) testing. \n\nWhere: Conrad Centennial\, Singapore\nWhen: November 13-14\, 2024\nWho: 100+ precision medicine experts from across the APAC region and wider globe\n\nDownload the event agenda here: https://ter.li/3qxsp8 \nThis unique and important forum is uniting experts from Singapore\, Australia\, China\, Japan\, Taiwan\, the USA and more to create a comprehensive framework for successful drug-companion diagnostic co-development and robust biomarker testing to accelerate patient access to personalized healthcare for improved outcomes in the APAC market. \nThis conference is FREE* to attend for drug developers and academics\, see the website for full terms and conditions here: https://ter.li/ewpxoe
URL:http://www.pharmajournalist.com/event/world-companion-diagnostics-liquid-biopsy-summit-apac/
LOCATION:Conrad Centennial\, 2 Temasek Blvd\, Singapore\, 038982\, Singapore
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR